Lv3
286 积分 2025-07-30 加入
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP -Deleted Cancer
1个月前
已完结
PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma
1个月前
已完结
Gastric Cancer
3个月前
已关闭
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
5个月前
已完结
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer
5个月前
已关闭
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
5个月前
已完结
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles
5个月前
已完结
537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
6个月前
已完结
Abstract P044: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas
6个月前
已关闭
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)
6个月前
已关闭
皖公网安备34019202002308
